| Author (Corporate) | European Medicines Agency |
|---|---|
| Series Title | Press Release |
| Series Details | EMA/CHMP/840800/2011 (20.10.11) |
| Publication Date | 20/10/2011 |
| Content Type | News |
|
The European Medicines Agency (EMA), on 20 October 2011, announced that it had agreed to the immediate recall of some batches of 0.5 mg prolonged-release hard capsules of Advagraf (tacrolimus) from pharmacies and wholesalers across the European Union. This followed detection of more active substance than expected being released from the capsules. Advagraf is used to prevent organ rejection in adults who have had a kidney or liver transplant or to treat organ rejection when other medicines have not worked. |
|
| Source Link | Link to Main Source http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2011/10/news_detail_001367.jsp&mid=WC0b01ac058004d5c1 |
| Related Links |
|
| Subject Categories | Health |
| Countries / Regions | Europe |
